Sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have drawn much attention both for being the first new treatments for advanced prostate cancer since docetaxel (Taxotere) was approved in 2004, and for their high costs. As described in Dr Newcomer’s accompanying piece, they will add significantly to the cost of care [ Read More ]
Yu-Ning Wong, MD, MSCE
Yu-Ning Wong, MD, MSCE, is assistant professor, Fox Chase Cancer Center and adjunct senior fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA and an editorial board member for Value-Based Cancer Care.
For all the talk about personalized medicine, in most cases the tools we have in oncology are more often disease site–focused than personalized. Each tumor type has a list of potentially active agents. For example, in kidney cancer, I can [ Read More ]